©2024 Stanford Medicine
Extended Access of Momelotinib in Adults With Myelofibrosis
Not Recruiting
Trial ID: NCT03441113
Purpose
The primary objective of this study is to provide extended access and assess long-term safety
of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia
vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies
GS-US-352-0101 (NCT01969838), GS-US-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746),
SRA-MMB-301 who are currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg
and 200 mg tablets) and have not experienced progression of disease. The secondary objective
is to assess overall survival (OS) and leukemia free survival (LFS) in all subjects.
Official Title
Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Eligibility
Key Inclusion Criteria:
- Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or
SRA-MMB-301
- Able to comprehend and willing to sign the informed consent form
Key Exclusion Criteria:
- Known hypersensitivity to MMB, its metabolites, or formulation excipients
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Intervention(s):
drug: MMB
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061